Preview

Научно-практическая ревматология

Расширенный поиск

ВЛИЯНИЕ АТОРВАСТАТИНА НА ДИНАМИКУ МАРКЕРОВ ВОСПАЛЕНИЯ ПРИ СИСТЕМНОЙ СКЛЕРОДЕРМИИ

https://doi.org/10.14412/1995-4484-2011-601

Полный текст:

Аннотация

Цель - изучить динамику серологических маркеров воспаления под влиянием длительного приема статинов у больных системной склеродермией (ССД).
Материал и методы. В исследование включены 40 больных ССД, которые были разделены на основную (n=22) и контрольную (n=18) группы. В основной группе дополнительно к проводимой терапии назначался аторвастатин в дозе 10 мг/сут в течение первых 6 мес, в последующие 6 мес - по 40 мг/сут у 12 и в прежней дозе у 10 больных. Методом иммуноферментного анализа в сыворотке крови определяли содержание высокочувствительного С-реактивного белка (вчСРБ) и интерлейкина (ИЛ) 6 исходно и через 3; 6; 9 и 12 мес в основной группе, а в контрольной группе - исходно и после 12 мес наблюдения.
Результаты. В основной группе содержание вчСРБ составило 5,54±4,41 мг/л и было повышено у 13 (59%) больных. Через 3; 6; 9 и 12 мес уровень вчСРБ составил 3,93±3,13; 2,95±2,27; 3,15±3,01 и 2,86±2,27 мг/л соответственно и был достоверно ниже исходного (p=0,002). В эти же сроки содержание вчСРБ снизилось на 25; 37; 35 и 35% от исходного уровня и оставалось повышенным у 10 (45%); 10 (45%); 9 (41%) и 6 (27%) больных. Уровень ИЛ 6 был повышен у 10 из 14 больных и превышал его содержание у здоровых доноров. Через 12 мес он уменьшился с 6,61±6,37 до 1,89±2,71 пг/мл (р=0,038), а частота повышения снизилась с 71 до 14% (р=0,007).
В контрольной группе уровень вчСРБ и ИЛ 6, как и частота повышения, через 12 мес не отличались от исходных результатов. Изменения уровня вчСРБ и ИЛ 6 за этот период в контрольной группе составили -0,42±2,32 мг/л и 0,14±4,15 нг/мл соответственно и были достоверно менее выраженными, чем в основной группе (р=0,036 и р=0,03).
Заключение. Аторвастатин при длительном применении проявляет стойкое противовоспалительное действие у большинства больных ССД.

Список литературы

1. <div><p>Гусева Н.Г. Системная склеродермия и псевдосклеродермические синдромы. М.: Медицина, 1993;268 с.</p><p>Charles C., Clements P., Furst D.E. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367:1683-91.</p><p>Smith G.P., Chan E.S. Molecular pathogenesis of skin fibrosis: insight from animal models. Curr Rheumatol Rep 2010;12(1):26-33.</p><p>Blann A.D., Illingworth K., Jayson M.I. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol 1993;20(8):1325-30.</p><p>Stuart R.A., Littlewood A.J., Maddison P.J., Hall N.D. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol 1995;13(1):17-22.</p><p>Scala E., Pallota S., Frezzolini A. et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004;138:540-6.</p><p>Алекперов Р.Т., Баранов А.А., Абайтова Н.Е. Клинические ассоциации С-реактивного белка при системной склеродермии. Тер арх 2006;78(6):30-5.</p><p>Akesson A., Scheja A., Lundin A., Wollheim F.A. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthr Rheum 1994;37(5):729-35.</p><p>Allanore Y., Borderie D., Lemarechal H. et al. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 2003;30(1):68-73.</p><p>Minier T., Nagy Z., Balint Z. et al. Construct validity evaluation of the European Scleroderma Study Group activity index, and investigation of possible new disease activity markers in systemic sclerosis. Rheumatology (Oxford) 2010;49(6):1133-45.</p><p>Scala E., Pallota S., Frezzolini A. et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004;138:540-6.</p><p>Bolster M.B., Ludwicka A., Sutherland S.E. et al. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthr Rheum 1997;40:743-51.</p><p>Hasegawa M., Sato S., Fujimoto M. et al. Serum levels of interleukin-6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp 130 in patients with systemic sclerosis. J Rheumatol 1998;25(2):308-13.</p><p>Varga J. Systemic Sclerosis. An Update. Bull NYU Hospital Joint Dis 2008;66(3):198-202.</p><p>Ridker P.M., Rifai N., Pfeffer M.A. et al., for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100(3):230-5.</p><p>Romano M., Mezzetti A., Marulli C. et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Invest Med 2000;48:183-9.</p><p>Albert M.A., Danielson E., Rifai N. et al. Effect of statin therapy on C-reactive protein levels-The Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.</p><p>Kinlay S., Schwartz G.G., Olsson A.G. et al., for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIR-ACL) Study Investigators High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study. Circulation 2003;108:1560-6.</p><p>Nissen S.E., Murat Tuzcu E., Schoenhagen P. et al., for the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) InvestigatorsStatin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease. N Engl J Med 2005;352:29-38.</p><p>Yoon S.S., Dillon C.F., Carroll M. et al. Effects of Statins on Serum Inflammatory Markers: The U.S. National Health and Nutrition Examination Survey 1999-2004. J Atheroscler Thromb 2010; 17 [Epub. ahead of print online ISSN:1880-3873].</p><p>Derk C.T., Jimenez S.A. Statins and the vasculopathy of systemic sclerosis: Potential therapeutics agents? Autoimmun Rew 2005;5(1):25-32.</p><p>Abou-Raya A., Abou-Raya S., Helmi M. 3-hydroxy-3-methyl glutaryl-coenzyme A (HMG-COA) reductase inhibitors (statins): a potentially valid addition to the therapeutic armamentarium of systemic sclerosis. Ann Rheum Dis 2006;65(Suppl. II):38.</p><p>Furukawa S., Yasuda S., Amengual O. et al. Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann Rheum Dis 18. 18.</p><p>Kuwana M., Kaburaki J., Okazaki Y. et al. Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthr Rhteum 2006;54(6):1946-51.</p><p>Del Papa N., Cortiana M., Comina D.P. et al. Clinical and biological evidences of improvement of vascular endothelial function by simvastatin in patients with systemic sclerosis. Ann Rheum Dis 2007;66(Suppl. II):207.</p><p>Masi A.T., Rodnan G.P., Medsger T.A. et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthr Rheum 1980;23(5):581-90.</p><p>Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet 1996;348:1079-82.</p><p>Corsini A., Bernini F., Quarato P. et al. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology 1996;87:458-68.</p><p>Ridker P.M., Rifai N., Pfeffer M.A. et al., for the Cholesterol and Recurrent Events (CARE) Investigators Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-44.</p><p>Sathyapalan T., Atkin S.L., Kilpatrick E.S. Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes. Diabetes Care 2010;33(9):1948-50.</p><p>Motomura T., Okamoto M., Kitamura T. et al. Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients. J Atheroscler Thromb 2009;16(5):546-52.</p><p>Devaraj S., Chan E., Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 2006;91(11):4489-96.</p><p>Bulcao C., Ribeiro-Filho F.F., Sanudo A. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Am J Cardiovasc Drugs 2007;7(3):219-24.</p><p>McCarey D.W., McInnes I.B., Madhok R. et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-21.</p><p>Grip O., Janciauskiene S. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS ONE 2009;4(5):e5263.</p><p>Goicoechea M., Vinuesa S., Lahera L. et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 2006;17:231-5.</p><p>Panichi V., Mantuano E., Paoletti S. et al. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. J Nephrol 2008;21(1):38-44.</p><p>Karaca I., Ikay E., Akbulut M. et al. Atorvastatin affects C-reactive protein levels in patients with coronary artery disease. Cur Med Res Opin 2003;19(3):187-91.</p><p>RiesenW.F., Engler H., Risch M. et al. Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 2002;23:794-9.</p><p>Albert M.A., Danielson E., Rifai N. et al. Effect of statin therapy on C-reactive protein levels-The Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.</p><p>Plenge J.K., Hernandez T.L., Weil K.M. et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106(12):1447-52.</p><p>Blum A., Costello R., Samsel L. et al. Variability of C-reactive protein levels among patients with stable coronary artery disease and on statin therapy. Isr Med Assoc J 2009;11(10):602-5.</p><p>Topol E.J. Intensive statin therapy - a sea change in cardiovascular prevention. N Engl J Med 2004;350:1562-4.</p><p>Bonnet J., McPherson R., Tedqui A. et al. CAP Investigators. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther 2008;30(12):2298-313.</p><p>Macin S.M., Perna E.R., Parias E.F. et al. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebocontrolled study. Am Heart J 2005;149:451-7.</p><p>Hong S.J., Choi S.C., Kim J.S. et al. Low-dose versus moderate-dose atorvastatin after acute myocardial infarction: 8-month effects on coronary flow reserve and angiogenic cell mobilisation. Heart 2010;96(10):756-64.</p><p>Panichi V., Paoletti S., Mantuano E. et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant 2006;21:337-44.</p><p>Singh U., Devaraj S., Jialal I., Siegel D. Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol 2008;102(3):321-5.</p><p>Keles T., Akar Bayram N., Kayhan T. et al. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels. Anadolu Kardiyol Derg 2008;8(6):407-12.</p><p>Li J.J., Li Y.S., Chu J.M. et al. Changes of plasma inflammatory markers after with drawal of statin therapy in patients with hyperlipidemia. Clin Chim Acta 2006;366(1-2):269-73.</p><p>Rashitchizadeh N., Argan H., Ghorbanihaghio A. et al. C-reactive protein level following treatment and withdrawal of lovastatin in diabetic nephropathy. Iran J Kidney Dis 2009;3(2):93-8.</p><p>Oka H., Ikeda S., Koga S. et al. Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases. Heart Vessels 2008;23(4):249-56.</p><p>Genest J. C-reactive protein: risk factor, biomarker and/or therapeutic target? Can J Cardiol 2010;26(Suppl. A):41-4.</p><p>Mora S., Ridker P.M. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) - can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 2006;97(2A):33-41.</p><p>Hattori Y., Matsumura M., Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res 2003;58(1):186-95.</p><p>Lin R., Liu J., Peng N. et al. Lovastatin reduces nuclear factor kappaB activation induced by C-reactive protein in human vascular endothelial cells. Biol Pharm Bull 2005;28(9):1630-4.</p><p>Venugopal S.K., Devaraj S., Yuhanna I. et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002;106:1439-41.</p><p>Verma S., Wang C.H., Li S.H. et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-9.</p><p>Verma S., Li S.H., Badiwala M.V. et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-6.</p><p>Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.</p><p>Torzewski M., Rist C., Mortensen R.F. et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:2094-9.</p><p>Asanuma Y., Oeser A., Stanley E. et al. Effects of C-reactive Protein and Homocysteine on Cytokine Production: Modulation by Pravastatin. Arch Drug Inf 2008;1(1):14-22.</p><p>Arnaud C., Burger F., Steffens S. et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol 2005;25:1231-6.</p></div><br />


Для цитирования:


Алекперов Р.Т., Korzeneva E.G., Aleksandrova E.G., Новиков А.А., Anan'eva L.P., Насонов Е.Л., Алекперов Р.Т., Korzeneva E.G., Aleksandrova E.G., Новиков А.А., Ананьева Л.П., Насонов Е.Л. ВЛИЯНИЕ АТОРВАСТАТИНА НА ДИНАМИКУ МАРКЕРОВ ВОСПАЛЕНИЯ ПРИ СИСТЕМНОЙ СКЛЕРОДЕРМИИ. Научно-практическая ревматология. 2011;49(2):40-46. https://doi.org/10.14412/1995-4484-2011-601

For citation:


Alekperov R.T., Korzeneva E.G., Aleksandrova E.G., Novikov A.A., Anan'eva L.P., Nasonov E.L., Alekperov R.T., Korzeneva E.G., Aleksandrova E.G., Novikov A.A., Ananyeva L.P., Nasonov E.L. EFFECT OF AT ORVASTATIN ON THE TIME COURSE OF CHANGESIN INFLAMMATORY MARKERS IN SYSTEMIC SCLERODERMA. Rheumatology Science and Practice. 2011;49(2):40-46. (In Russ.) https://doi.org/10.14412/1995-4484-2011-601

Просмотров: 502


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)